Studies on the hypotensive actions of coptis chinensis and its components in rats. by Chun, Yiu-to. & Chinese University of Hong Kong Graduate School. Division of Biochemistry.
STUDIES ON TIE HYPOTENSIVE ACTIONS OF COPTIS CHINENSIS




A THESIS SUBMITTED IN PARTIAL FULFILMENT OF






THE CHINESE UNIVERSITY-OF HONG KONG

2ACKNOWLEDGEMENT
I would like to express my sincere gratitude to
Dr. Y.C. Kong for his guidance and valuable suggestions
during the course of this study.
I am also greatly indebted to Prof. Frederick
F. Kao, Dr. Joseph C. Hwang, Dr. Y.M. Choy and Dr. H.W.
Yeung for supervision and many helpful discussions, and
to Prof. U. Sankawa for his help in spectroscopic analysis.
Ply grateful thanks are due to Prof. L. Ma for
his guidance.
I also wish to thank Mr. T.T. Yip, Miss K.L. Lau,




1.1 REGULATION MECHANISMS ON BLOOD PRESSURE 1
1.2 CAUSE AND TREATMENT OF HYPERTENSION 9
1.3 USE OF HERBAL MEDICINE IN THE
TREATMENT OF HYPERTENSION 16
1.4 Coptis chinensis 19
2. E XPE RIME14TAL
22
2.1 EXTRACTION AND PURIFICATION OF
Coptis chinensis ALKALOIDS 22
2.1.1 Column chromatography 22
2.1.2 Thin-layer chromatography 24
2.2 SPECTROSCOPIC ANALYSIS 24
2.2.1 UV-visible spectroscopy 24
2.2.2 IR spectroscopy 25
2.2.3 NMR spectroscopy 25
2.3 DETERMINATION OF BERBERINE CONTENT IN
Coptis chinensis CRUDE EXTRACT 25
2.4 PHARMACOLOGICAL STUDIES 26
2.4.1 The animal model 26






2.5.2 Rat auricular cholinesterase 28
2.6 STATISTICAL ANALYSIS 29
3. RESULTS
30
3.1 PHYTOCHEMICAL PROPEP.TIES OF
Coptis ch inensis 30
3.1.1 Crude extract
30
3.1.2 Purification of total
alkaloid fraction 30
3.1.3 Spectroscopic analysis 32
3.1.3.1 UV-visit Ze spectra 32
3.1.3.2 IR spectra
32
3.1.3.3 NMR spectra 37
page NO
43.2 PHARMACOLOGICAL OBSERVATIONS 37
3.2.1 Effects of intravenous infusion of
Coptis chinensis crude extract on
blood pressure and heart rate 37
3.2.2. Effects of intravenous infusion of
berberine on blood pressure and
heart rate 42
3.2.3 Effect of intravenous infusion.of
berberine on blood pressure in
the presence of ansolysen 46




3.3.2 Rat auricular cholinesterase 54
4. DISCUSSIONS 60
4.1 ACTUIONS OF Coptis chinensis CRUE EXTRACT
AND BERBERINE ON BLOOD PRESSURE 60
4.2 ACTION MECHANISM OF BERBERINE
63
4.3 ACTION OF BERBERINE ON ACETYLCHOLINESTERASE 65





Hypertension is the presence of unnecessarily increased
pressure within the blood vessels generated by the heart
consonant with the elastic recoil of the great vessels.
(systolic pressure) and the muscular resiliency of the vast
plexus of arterioles (diastolic pressure).. -It is the most
common of the chronic diseases. In a recent survey of Euro-
pean and North American adults, 10- 15% were found to be
hypertensive (Mahler, 1978) in China, according to investi-
gations in recent years, the morbidity of hypertension is
about 3- 4% in young people, 5- 10% in middle-aged people,
and over 15% in people over 50 years old (anon. 1976a1_
riypertenslon is a major health problem because. people
with high blood pressure are more likely to have strokes,
heart diseases, or kidney failures. It should not be treated
as an independent phenomenon because, in addition to producing
other symptoms, it may also be the consequence of other body
abnormalities such as that in nervous system, endocrine
.system, kidneys and heart. Therefore a brief account of the
overall blood pressure regulation is appropriate.
1.1 REGULATION MECHANISMS ON BLOOD PRESSURE
The cardiovascular function is governed by a fundamental
equation, which states that the blood pressure is equal to the
peripheral resistance times the cardiac output. Despite its
2simplicity, the details concerning the regulation on each
parameter are highly complicated involving-the interactions
between the circulatory, nervous, .endocrine and excretory
systems.
Blood pressure control mechanisms can be divided into
three different groups according to the rapidity of responses:
(1) Short-term mechanisms with a time course in
seconds these involve the nervous and some humoral controls.
(2) Intermediate-term mechanisms with a time course in
minutes these involve the fluid-shift mechanism, myogenic
response of vasculature, and some humoral controls.
(3) Long-term mechanisms with a time course in hours
and may even last for months and years these may concern
chiefly with the kidney (Guyton et aZ., 1974).
It is well-known that the autonomic nervous system plays
a key role in the instant regulation of cardiovascular
function. This regulation may respond to both external and
internal stimuli, and may involve the higher brain areas or
through the reflex mechanisms. These subjects have been
critically reviewed recently (Oberg, 1976 Smith, 1974).
The emotional influence on cardiovascular performance is
well-known. The internal stimuli form a part of the feed-
back system which is achieved by the specific sensors located
in various parts of the cardiovascular system. These sensors
include the carotid sinus and aortic arch barorecentrs_
3cardiopulmonary receptors and carotid and aortic body chemo-
receptors. The various types of receptors can detect changes
in blood pressure, pH, P02, PcC)2 etc., and initiate compen-
satory reflex adjustments through the autonomic regulation
involving most directly the hypothalamus and medulla oblon-
gata. Somatic afferents can also modify cardiovascular
function through the spinal reflex (Sato and Schmidt, 1973).
The heart and most blood vessels except the capillaries
are richly innervated by autonomic nerve fibres, with sympa
thetic components more predominant in ventricles and arteries.
Neural transmission are cholinergic in preganglionic and post-
panglionic parasympathetic pathways, and are adrenergic in
most postganglionic sympathetic pathways. In general, sympa-
thetic stimulation leads to positive inotropic and chrono-
tropic responses, together with vasoconstriction in most
organs, with an overall increase in-blood pressure as the
consequences of increased cardiac output and peripheral
resistance.
In contrast, parasympathetic stimulation leads to vaso-
dilatation, but the effect on vascular performance is less
significant than that by sympathetic modification, and the
vasodilatation in most vascular beds is mainly contributed by
the reduction of sympathetic tone. However, parasympathetic
control in heart (the vagus) is important, and the cardiac
performance is a result of balance between sympathetic and
4vagal contributions. Vagal stimulation reduces sinus rate
and depress atrial contractility and conduction through the
atrioventricular node (Sarnoff and Mitchell, 1961). However,
stimulation of cholinergic fibre only exerts minor negative
inotropic effects on the ventricles (Higgins et ai., 1973)
instead, the negative chronotropic influence of acetylcholine
is predominant compared with norepinephrine.
The diversity of actions by different neurotransmitters,
as well as that by the same transmitter at different sites,
has led to the receptor concept. The a and adrenergic
receptors are well-known (Ahlquist, 1948). More recent study
further differentiates the latter into and 2 subgroups
(Lands et aZ., 1967), and the cardiac -adrenergic receptor
protein has actually been isolated from dog ventricle
(Lefkowitz et aZ., 1972 Alexander et aZ., 1975). Activation
of a-receptors leads to vasoconstriction. Activation of
r31-receptors leads to cardiac stimulation, that of 2-
receptors leads to vasodilatation. Norepinephrine is more
potent towards a-receptors, therefore sympathetic activation
in most vascular beds leads to vasoconstriction.
Cholinergic receptors are classified as muscarinic or
nicotinic on the basis of their similarity to responses to
alkaloids muscarine and nicotine. Nicotinic receptors are
mainly located in skeletal muscle, autonomic ganglia, medulla
oblongata and the brainstem. Muscarinic receptors are mainly
5located in smooth muscle, glands, and the cerebrum. Direct
activation on cardiovascular muscarinic re-ceptors leads to
vasodilatation and hypoactivity of the heart. However,
ganglionic activation leads to opposite results due to acti-
vation of postganglionic sympathetic pathway.
The role of cyclic nucleotides in cardiovascular funct.Lon
has been evoked in recent years. Although cyclic AMP has been
implicated by some investigators as the mediator of
catecholamine-induced positive inotropic response, its exact
role in cardiac contractility has been questioned (Sobel and
Mayer, 1973 Venter et al,, 1975). On the other hand, there
is increasing evidence implying a role for cyclic AMP in
vascular relaxation (Anderson, 1973 Cohen and Berkowitz,
1974 Trinter et aZ., 1972 Volicer and Ilynie, 1971), although
change in cyclic AMP level may not provide the sole mechanism
(Needleman et aZ, 1973). It has been demonstrated that
activation of cholinergic receptors in the heart evokes a
large transient increase in cyclic GMP levels, but the
consequences are not known (George et aZ., 1970).
Besides nervous control, humoral factors may also
participate in the short- and intermediate-term control of
blood pressure. These include the adrenal medullary hormones,
vasopressin, and the r.enin-angiotensin- aldosterone system.
The adrenal medulla can be considered to be a part of the
total sympathetic mechanism. Although extensively studied,
6the importance of the adrenal medulla in normal- circulatory
control remains unknown. However, its role may be crucial
after inhibition of sympthetic vasoconstrictor responsiveness
(de Champlain and van Amerigen, 1972). Vasopressin can-be
released by stimulations in the hypothalamus. It constricts
blood vessels, but its physiological role on vasoconstriction
is doubtful.
Renin is an enzyme released from the kidney which can
split the angiotensinogen of hepatic origin into angioten-
sin I this peptide can then be splitted further into angio-
tensin II by a converting enzyme. Several mechanisms,
including a change in the wall tension of renal afferent
arterioles, a change in sodium concentration or load in
distal tubules, as well as certain pathological states,
appear to influence renin release (Assaykeen and Ganong,
1971 Davis, 1973). There are also evidences suggesting that
the sympathetic nervous system plays a major role in the
release of renin. The plasma renin activity (PRA) is proba-
bly mediated by 2-adrenergic mechanism (Johnson et al. ,
1976). The actions of angiotensins on the blood pressure are
highly complicated. These include direct vasoconstriction,
augmentation of cardiac contractility under certain circums-
tances, stimulation of aldosterone secretion, as well as
numerous indirect effects (Sweet, 1977). Aldosterone parti-
cipates in intermediate- as well as long-term blood pressure
7control by influencing renal sodium reabsorption. Angioten-
tensins can also enhance norepinephrine release from sympa-
thetic nerve endings in some organs and potentiate sympathe-
tic reflex (McCublin et aZ., 1965 Zimmerman et aZ., 1972).
Normally circulatory levels of angiotensins probably do not
affect vascular tone. However, during sodium depletion or
haemorrhage, angiotensins probably contribute to homeostatic
regulation of arterial and renal blood flow, as well as
aldosterone secretion (Freeman et aZ., 1973 Spielman and
Davis, 1974 Thurston and Laragh, 1975). Angiotensin II has
recently been found to have central vaso.pressor activity
which may be closely associated with central a-adrenergic
receptor mechanism, and with its ability to release vaso-
pressir (Buckley, 1977). However, it would seem premature to
conclude that there is a functional brain renin-angiotensin
system, and the significance of the angiotensin receptors
that are inside the blood-brain barrier is not clear (Reid,
1977).
Apart from neural and systemic humoral control, the
local control of circulation is very important in capillary
beds,. and probably in cerebral. circulation as well. This
autoregulation mechanism is responsible for the metabolic
state of various tissues, as well as the physical state of
local circulation. The factors include myogenic response,
.tissue osmolarity, oxygen and carbon dioxide tensions, pH,
potassium and adenosine (Johnson, 1974). Although the exact
8manner of interactions between the prostaglandins and the
cardiovascular and nervous systems- are not clear, it' is
generally believed that they participate in the local control
of renal blood flow (e.g. Herbacynska-Cedro and Vane 1973
Lonigro et aZ., 1973). It has also been suggested that
prostaglandins are local regulators of microvascular respon-
siveness in skeletal muscle, and may modulate vasoconstric-
tor responses to angiotensins and norepinephrine (Messina
et aZ., 1975).
Nervous control mechanisms are ideally suited to short-
term circulatory control because they respond very quickly.
They are directed predominantly towards maintanence of
systemic blood pressure rather than cardiac output (Liedtke
et aZ., 1973). However, it is suspicious that the reflex
control plays an important role in the long-term regulation of
blood pressure because evidence definitely indicate that the
entire reflex control adapt in a few days to the existing
.level of arterial blood pressure (Sagawa et aZ, 1974).
Based on this. and several observations on experimental hyper-
tension, Guyton and associates (Coleman et al., 1974 Guyton
et aZ., 1972 Guyton et aZ., 1974) suggested that the kidney
functions as a primary long-term regulator of blood pressure.
A direct relationship exists between systemic blood pressure
and urine output. Thus, any variation in blood pressure
initiates a compensatory change in urinary volume and, in
9turn, plasma volume, which will tend to return blood pressure
to normal. These adaptations, of course, imply adequate
renal function. Disease states which affect renal function
may adversely modify urinary output curve, thus severely
straining this homeostatic process.
1.2 CAUSE AND TREATMENT OF HYPERTENSION
Established hypertension refers to a state when the
systolic pressure is persistently 160 mmHg and/or the di as-,.
tolic pressure is 95 mmHg or more (World Health Organization,
1962). Mild hypertension may be diagnosed if the diastolic
pressure is between 95 and 109 mmHg, and severe hypertension,
if it is 130 mmHg or more..
Presently, only approximately 10% of patients can be
ascertained to have a definable cause of hypertension (De
Quattro et al., 1977). Hypertension in this case is called
symptomatic or secondary. Unfortunately, the majority of
cases are of primary, or essential type, in which the primary
cause is unknown. Current hypotheses concerning the causes
of essential hypertension include:
(1) Neurogenic: Since many patients with essential
hypertension exhibit similar autonomic features, there has
been a popular clinical impression that the sympathetic
nervous system is important in the genesis of essential
hypertension. This hypothesis is strengthened by the find-
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ings of Louis et al. (1973) which relates the fall in blood
pressure to the fall in plasma catecholamines after gan-
glionic blockade.
(2) Nephrogenic: According to Guyton et aZ. (1972),
an increase in arterial blood pressure will lead to a marked
increase in urinary output via a direct haemodyamic effect of
arterial pressure itself and indirectly by inhibition of all
factors which lead to the conservation of salt and eater.
Although the urinary output has been found to be normal in
early essential hypertension, actually salt and water excre-
tion is achieved at the expense of increased arterial pres-
sure. The nephrogenic hypothesis is supported by several
recent observations which suggest an antihypertensive
function of the normal kidney (Terragno and Terragno, 1977).
Although no definite relationship between hypertension and
the renin-angiotensin system has been found, classification
of hypertension according to plasma renin activity may offer
a: good guide to a more rational basis for antihypertensive
therapy in the future (Johnston, 1976 Laragh et a Z., 1972).
'1'ne Dlocfemical events in hypertension has also been
investigated recently. Decreased vascular cyclic A y1P levels
have been reported for spontaneously hypertensive and stress
hypertensive rats (Amer, 1973). In neurogenically hyperten-
sive rats, heart cyclic A11P level decreases, while the cyclic
GIMP to cyclic AT1P ratio, cyclic AMP phosphodiesterase and
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guanylyl cyclase activities in the aorta increase, and sensi-
tivity of adenylyl cyclase in both the aorta and heart to
stimulation by the S-adrenergic stimulant isoproterenol
decreases (Amer et aZ., 1975). The decreased relaxation
response of aortic strips to cyclic AMP and isoproterenol is
also observed in spontaneously and renal hypertensive rats
(Cohen and Berkowitz, 1976). To account. for the possible
structural alternations of blood vessels during hypertension,
elevated lysine incorporation into the non-collagenous
protein of mesenteric arteries is observed in spontaneous
hypertensive rats. This process can be abolished by
ganglionic blocker, but not by vasodilator. This suggests
. that. the sympathetic innervation' is important for the
increased, synthesis of vascular non-collagenous protein
during hypertension (Yamori et aZ., 1976).
Owing to the extremely complicate situation in cardio-
vascular regulation, therapy for hypertension has been a
difficult problem. Nowadays treatments of essential hyper-
tension are mainly palliative rather than curative. In the
1940s there was little hope of preventing death from malig-
nant hypertension, cardiac failure, hypertensive encephalo-
pathy, or from other major complications of hypertension.
However, since the prospective studies has shown that with
efficient and safe modern antihypertensive drugs, cardio-
vascular morbidity and mortality in the hypertensive patients
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can be dramatically reduced. It is generally believed that
pharmacotherapy is for most patients the primary treatment of
choice in hypertension.
The pharmacotherapy of hypertension began in 1948 since
the introduction of ganglionic blockers. They reduce blood
pressure by reducing sympathetic outflow. However, because
they also interfere with parasympathetic function, they can
cause side effects and have been largely replaced by newer
drugs. Currently employed drugs can be divided into four
groups according to their mode of action (TNollam et aZ.,
1977): 1. diuretics, 2. sympathoplegic drugs, 3. vasodila-
tors, and 4. angiotensin II analogues and converting enzyme
inhibitors. They can be further subdivided according to
their exact site of action.
Although the exact antihypertensive mechanism of
diuretics is still not clear, it is probably due to the
persistent reduction of plasma and extracellular fluid
volume (Leth, 1970 Terazi et aZ., 1970).
Sympathoplegic drugs constitute the largest body of
current antihypertensive drugs. They act on specific sites
of-the nervous system. The use of ganglionic blockers such
as pentolinium (Ansolysen) is usually restricted to severe
cases. The antihypertensive action of reserpine is well-
known. Reserpine and guanethidine, although exerting
different biochemical effects, both act at the level of the
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neuroeffector junction by interfering with the release of
norepinephrine (Gaffney et aZ., 1963 Hertling et aZ., 1962).
Clonidine and a--methyldopa are typical centrally-acting anti-
hypertensive drugs, the action of the latter probably
involves the false transmitter mechanism in which a-methyl--
dopa is converted to a-methyl-norepinephrine (Day and Rang,
1964 Kobinger, 1975). a-Methyldopa also has a peripheral
action (Lokhandwala et aZ., 1976). Prazoin was originally
classified as a direct-acting vasodilating agent but recent
evidence suggests that it primarily acts as a postsynaptic
a-adrenergic blocker (Bolli et aZ., 1975). 13-Adrenergic
blockers lower blood pressure by decreasing peripheral
resistance, their effects appear to be dissociated from renin
release (hooker j ee et a l., 1977 Nies and Shand, 1575). The
antihypertensive action of the monoamine oxidase inhibitor
pargyline is not clear, but because of the food-restriction
and lethal side-effects, its use should be discouraged
(ol lam et aZ., 1977)
The vasodilators hydralazine, diazoxide and minoxidil
exert their effects on arterial circulation only, the reflex
increases in heart rate and cardiac output retard their anti-
hypertensive effects. But sodium nitroprusside causes veno-
dilatation as well so the problem of increasing cardiac
output can be avoided. However, it must be administered by
continuous intravenous infusion due-to its rapid decline of
14
action (Wollam et aZ., 1977)
The angiotensin II antagonists and converting enzyme
inhibitors are still under investigation. It may be import-
ant in the hypertension which largely involves the. kidney and
the renin-angiotensin system.
A summary of the development of antihypertensive drugs
is shown in Fig. 1.
Because of the close interdependency between haemody-
namic parameters and the nervous system, serious adverse
effects is often a problem in the chemotherapy of hyperten-
sion, and the treatment should not be aimed alone at blood
pressure but also at the whole cardiovascular performance
which is related to the stage of hypertension (Frohlich,
1977). As a consequence, combination therapy is usually
necessary. For example, the vasodilator hydralazine is often
used together with a diuretic and the a-blocker propranolol.
Propranolol prevents the tachycardia and increase in cardiac
output induced by hydralazine. The concomitant administra-
tion of a diuretic greatly potentiates the effect of pro-
pranolol.
Future progress of chemotherapy for hypertension
depends on two factors: viz. elucidation of hypertensive
mechanism, and new and better drugs. There is no reason to
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Fig. 1 A graphic representation of the development
of antihypertensive drugs (After Xu 1975)
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by hitherto unknown mechanisms. This, together with the
rationale for combination therapy, suggest that a search
in traditional Chinese medicine should provide valuable
informations.
1.3 USE OF HERBAL MEDICINE IN THE
TREATMENT OF HYPERTENSION
The use of naturally occurring compounds in medicine is
not a new idea. Reserpine and related Rauwo Z fia alkaloids in
the treatment of hypertension provide-.a good example.
One feature of the currently employed antihypertensive
drugs is the rather high degree of specificity. On the con-
trary, drug actions of traditional Chinese medicine are
usually obscure. This may be partly due to the poor under-
standing of body functions at the tissue level but more
importantly, this may be due to the different concepts in
diagnosis and treatment in Chinese medicine.
Records describing circulation were found in Chinese
classics for more than two thousand years ago ("Huang Di Nei
Jing", anon). In Chinese herbal pharmacy there is a group
of traditional medicine classified as "blood-managing drugs".
yet there is no definite diagnosis and therapy aiming at
hypertension as it is defined in modern biomedical context.
This is quite understandable if we consider that in tradi-
tional Chinese medicine more attentions are paid to the
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restoring of whole-body homeostatsis rather than to aim at
individual symptoms.
In traditional Chinese medicine, blood pressure is
considered governed by the functional balance between the
liver and the kidney. Actually these may not be totally
equivalent to the same organ in structure and fun ct ion (e.g.
anon, 1976b Chen et aX., 1977). The onset of hypertension
is thought to involve hyperactivity of the yang component
of liver function, this may appear as symptoms of the
excited state of the body such as dizziness, headache,
tinnitus aurium and irascibility. As the disease progresses,
the hyperactivity can destroy the ying component of liver
function which may exhibit, in addition, weakness, thirst
and constipation. Further development of disease may
ultimately affect the kidney, resulting in the exhaustion of
both the ying and yang components and therefore an
overall hypoactivity of the body. At the final stage,
the general weakness may extend to the brain (stroke), and
the disease becomes lethal.
As in the case of western medicine, the treatment of
hypertension is dependent on the stage of development of the
disease, although in this case the whole performance of the
body is emphasized. For the hyperactivity of liver
function, drugs of a. cool nature are employed to lower the
activity of the liver
平 肝 潜 陽 For the second stage,
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drugs are used to enrich the "ying" component but suppress
the "yang" component. In the third stage, therapy is ermmpha-
sized on the enrichment of body function. In the final
stage, the "cool" influence to the head is to be removed.
Because of this complexity, it should not be surprising to
find that the herbal medicine for .hypertension distributes
widely in many categories. These may include:
"ying-enriching agents" (,e.g.Loranthus
parasiticus
"yang-enriching agents" (),e.g. Eucommia
ulmoides
agents causing general hypoactivit
e.g. Uncaria rhynchophylla, Siegesbeckia pubescens
"anti-pyretic agents"() e.g. Cassia tora,
Coptis chinensis, Gardenia jasminoides,
Scutellaria baicatensis
"blood-mobilizing agents" (活血药) e, g. Salvia
miltiorrhiza
"diaphoretic agents" (解表药), e. g. Pueraria lobata
"digestive agents" (消道药), e.g. Crataegus pinnatifida
The exact action mechanisms of these agents are mostly
unknown, and the therapeutic value is mainly concluded from
the accumulation of clinical experience. However, in recent
years active components have been isolated from several
herbs and some of the action mechanisms have been partially
clarified. For example, vasodilatation may be responsible
for the hypotensive effect of Scutellaria baicaZensis and
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Pueraria Zobata (Tang and Chow, 1958 Fan et aZ., 1975),
while hypotensive effect of Cassia tora and Gardenia
jasminoides may be due to a modulation of cardiovascular
reflex mechanisms (Chan et aZ., 1976 Koo and Li, 1977).
In a series of exploratory studies, several plant
extracts have been tested for their acute hypotensive acti-
vity on arterial blood pressure in normotensive rats, these
include Ilex pubescens, Siegesbeckia pubescens, Eucommia
uZmoides and Coptis chinensis. Among them the hypotensive
effect of Coptis chinensis was found to be most responsive
in the present animal model.
1.4 Coptis chinensis
Coptis chinensis Franch. is a plant of the family
Ranunculaceae. It is a perennial herb with yellowish,
often branched rhizoid stems. The basal leaves are tri-
partite with hard and paperly textures and serrated
margins. Flowers are small and occur in clusters of 3- 8.
Mainly distributed in the provinces of Sichuan, Hubei and
Shanxi, small quantities are also found in Guizhou, Hunan
and Zhejiang. It usually grows in wet forest shades. The
rhizomes are used in traditional medicine.
Plants of the same genus C. de Ztoidea C .Y. Cheng et
Hsiao and C. teetoides C.Y. Cheng are also used in China.
The former is mainly distributed in Sichuan province, the
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latter in the northwest of Yunnan province
Coptis chinensis has been used in traditional medicine
for more than one thousand years. Chen in the Tang dynasty
(ti 710- 740) stated that this herb could be used to cure
weakness and asthma. Other features and use of this plant
can be found in many subsequent herbal records. I t is
classified as cool nature in traditional medicine, having
the effects of anti-pyretic, anti-wet and detoxication.
It has been used generally against irascibility, palpita-
tion, jaundice, vomiting, dysentery, hemorrhoid, hot dis-
eases, wet diseases, thirst, insonmia and sores etc.
When used alone, the usual oral dose is about?- 10 gm of
dry material. It is also.used in multiple-item prescrip-
tions. For example, it can be used in conjunction with the
hot agent Evodia rutaecarpa in the treatment of some gas-
trointestinal diseases (Zuo Jin Wan,
Another famous prescription is the Huang Lian Jie Du Tang
which is composed of Coptis chinensis and other
anti-pyretic agents ScuteZZaria baicaZensis, PheZZodendron
amurense and Gardenia jasminoides' it is an effective detox-
ication formula (Wang, Tang-dynasty).
Parallel to folkloric uses, several'pharmacological
effects of Coptis chinensis have been observed in this
century, these include the antibiotic, antifungal, anti-
viral, antiamebic and hypotensive effects (abstracts in Liu,
左 金 丸 (Zhu, ~1350)
黄 连 广 毒 汤
1963). The most well-known effect is the antibiotic effect,
which was observed in a traditional prescription (Xiang Lian
where Cop ti s chi ne ns i s is the main component
(hang, 1958). Berberine is found to be the major component
in. Coptis chinensis (Zhao, 1951). Berberine has pronounced
antibiotic effect (Lan et aZ., 1957).
As the primary cause of hypertension may involve the
hyperactivity of the "liver", it is reasonable to think
that hypotensive agents may exist in some anti-pyretic
herbs. Berberine has been demonstrated to exert transient
hypotensive effect in dog (Jang, 1953). In vitro studies
showed that berberine could modulate the effect of acetyl-
choline on heart performance (Jang, 1941), this might be due
to inhibition of berberine on cholinesterase, as demonstra-
ted by in vitro studies using horse serum cholinesterase
(Jang, 1953). However, the exact in vivo-events are
unclear. This study is an attempt to locate the site of
action of active components of Coptis chinensis and to
propose possible action mechanisms.
Wan 香 連 九
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2. EXPERIMENTAL
2.1 EXTRACTION AND PURIFICATION OF
Coptis Chinensis ALKALOIDS (Fig. 2)
Dry rhizomes of Coptis chinensis were purchased from
the herbal stores. It was originated from the Sichuan pro-
vince in China. One kilogram of material was cut into small
pieces and then ref luxed with 95% ethanol at 70- 80°C for
three hours. Refluxing was performed four times, each time
the extract was filtered while it was still hot. After
standing overnight at room temperature, the precipitates were
filtered and the filtrate was concentrated in a rotavapor
under reduced pressure. To the concentrated solution, 6N
hydrochloric acid was added dropwise until no more precipitate
was formed. These two batches of precipitates were combined
as the total alkaloid fraction. From 1 kg of dry material,
25 gm of total alkaloid fraction were obtained.
A portion of this fraction was recrystallized three
times in 95% ethanol at about 80°C. Components in this
recrystallized product were then separated by means of column
chromatography.
2.1.1 Column chromatography
Silica gel (E. Merck, 70- 230 mesh ASTM) was activated
by heating at 110°C overnight before packing. The solvent
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Fig. 2 Extraction and purification of
Coptis chinensis alkaloids
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packed to a diameter-height ratio of 1:10. The sample loaded
on the column was 1% by weight of the adsorbent. The same
solvent system was used for elution and 20-ml fractions were
collected. The fractions were monitored by means of thin-
layer chromatography. The peak fractions were designated
B1, B2, B3, according to the order of elution from the column.
2.1.2 Thin-layer chromatography
0.25-mm thick silica gel G (type 60) plates were used.
They were activated at 110°C for 1 hour before use. Two
solvent systems were employed:
(1) chloroform- methanol (6:4 .v/v)
(2) butanol- acetic acid- water (4:1:2 v/v).
Detection was by:
(1) UV light
(2) spraying with Dragendorff reagent.
2.2 SPECTROSCOPIC ANALYSIS
2.2.1. UV-visible spectroscopy
B1, B2 and berberine were dissolved in methanol and
absorbances were scanned from 220 to 500 nm in 1-cm thick




The sample powder was mixed with KBr (1/100 by weight)
and pressed into a thin disc of 0.1 mm thickness. Spectra
were obtained with Beckman IR10 spectrometer.
2.2.3 NMR spectroscopy
Samples were dissolved in deuteromethanol, NMR spectra
were obtained with -Jeol PS-100 NMR spectrometer through the
courtesy of Prof. U. Sankawa, Tokyo University.
2. 3 DETERMINATION OF BERBE RI NE CONTENT IN
Cop tis chinensis CRUDE EXTRACT
The material for pharmacological studies was prepared by
dissolving the total alkaloid salts in water. An aqueous
solution of the sample was prepared at a concentration of
30 mg/ml by heating at 80°C. On cooling, the precipitates
were removed. The supernate was referred as the crude extract
and was used for pharmacological studies. To determine the
true concentration in the supernate, an aliquot was lyophi-
lized to get the dry weight of substance dissolved in the
supernate. A quantitative estimation of berberine content was
also performed.
In this method, known quantities of the supernate and
standard berberine hydrochloride (Sigma) were applied on the
same plate and developed with chloroform- methanol (6:4 v/v).
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Spots of berberine were scraped and eluted with ethanol. The
absorbances of these eluates were' measured at 265 nm. After
adjusting for loss, the true concentration of berberine in the
sample could be calculated.
The contents of potassium, sodium and calcium in the
crude extract were measured with a'EEL Flame Photometer.
2.4 PHARMACOLOGICAL STUDIES
2.4.1 The animal model
Experiments were performed on Simnosen albino rats of
both sexes weighing 250- 350 gm. Animals were allowed normal
diet and water ad Libitum before experiment. In nembutalized
rats (40 mg/kg, i.p.), tracheal cannulation was made first.
A 1-cm segment of left carotid artery posterior to the thyroid
gland was then isolated and joined to portex tubing filled with
heparinized saline (50 u/ml). The blood pressure was allowed
to be stabilized each time before drug administration.
Blood pressure and heart rate measurements were made by
connecting the arterial catheter to a Statham P23 Db pressure
transducer coupled to a Beckman*9872 strain gauge coupler in a
Beckman 511A dynograph.
2.4.2 Dosage form and route of administration
uruae c,op vzs cfznensz s extract was dissolved in physio-
logical saline at an infusion dose of 9.0 mg/kg/hr. Berberine
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hemi-sulfate (Sigma) and compound B1 from the plant were dis-
solved in 5% glucose at an infusion dose of 10.0 mg/kg/hr.
When administered with ansolysen, the concentration of ber-
berine was doubled. Ansolysen (pentolinium tartrate, May &
'Baker) was dissolved in physiological saline at an infusion
dose of 500 pg/kg/hr.
-Test materials were normally administered by intra-
venous infusion through a right femoral vein catheter. When
two kinds of materials were infused concomitantly, an addi-
tional catheterization was made in the left femoral vein.
Infusion was kept at a rate of 1 ml/hr, each dose was adminis-
tered within one hour.
To study the interaction between ansolysen and berberine,
ansolysen alone was infused during first 30 minutes, then
berberine was infused concomitantly through an additional
femoral vein catheter and the infusion continued for another
30 minutes.
2.5 ENZYME ASSAY
2.5.1 Bovine erythrocyte acetylcholinesterase
Enzyme and all reagents were dissolved in 0.1 M phos-
phate buffer, pH 7.6.
Acetylthiocholine iodide and bovine erythrocyte acetyl-
cholinesterase were obtained from Sigma Co. The enzyme had a
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specific activity of 3.3 u/mg.
The assay procedure was modified after Ellman et aZ.
(1961). 10 it of 2 mg/ml acetylcholinesterase were added to
3 ml of 0.423 m.D4 5, 5' -dithiob isnitrobenzoic acid (DTNB,
Sigma). After incubating at 37°C for 15 minutes, 20 u1 of
0.075 M acetylthiocholine iodide were added.and the absorbance
was followed at 412 nm with Beckman Model 25 double-beam
spectrophotometer. Enzyme activity was expressed in uM/min.
2.5.2 Rat auricular cholinesterase
Rat auricles were excised, weighed and suspended in 1%
Triton-X 100 in a ratio of 1:10 (w/v). The preparation was
then homogenized with a Polytron homogenizer (type PTA-10-35).
The homogenate was centrifuged at 15,000 x g for 10 minutes
in a Sorvall RC2-B centrifuge. An aliquot of 100 ul l of the
supernate was used in each enzyme assay. The assay procedure
was identical to that described for bovine erythrocyte acetyl-
cholinesterase.
Non-specific cholinesterase activity was suppressed by
50 pl of 0.4 mM tetraisopropyl phosphoramide (iso-OMPA, Sigma)
added before incubation. Specific acetylcholinesterase
acitivity was suppressed by 30 U1 of 1 mM 1, 5-bis-4-211yl-




All data obtained were expressed as mean ± S .E .M., with
(n) denoting the frequency (number of animals/samples tested).
Mean blood pressure was indicated by the arithmetic mean of
the systolic and diastolic pressures. Data were statistically
analyzed using the paired t-test.
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3. RESULTS
3. 1 PHYTOCHEMICAL PROPERTIS OF
Coptis chinensis EXTRACT
3.1.1 Crude extract
Crude extract from Coptis chinensis contained yellow,
needle-shape crystals. The solubility in physiological
saline was 3 mg/ml at room temperature it was much more
soluble at higher temperature. It could be separated into
three distinct fluorescent, Dragendorff-positive spots by
means of SiO/2 thin-layer chromatography in different solvent
systems (Fig. 3). Berberine constituted 53% by weight of the
crude extract. Ion concentrations in the infused solution
were 2.9 x 10 /-4 M for potassium, 1.1 x 10-2 M for sodium and
1.7 x 10/-3 M for calcium.
3.1.2 Purification of total alkaloid fraction
This fraction could further be separated into three
main fractions by passing through the column and monitored
by means of thin-layer chromatography using the same solvent
systems for crude extract (Fig. 3). The three components were
designated B/1, B/2 and B/3 according to the order of elution
from the column. B/1 was yellow crystal, B/2 was orange-
coloured crystal, and B/3 was also orange in colour.










crude B1 B2 B3 berberine
extract
crude B1 B2 B3 berberine
extrat
Solvent CHCl3- McOH (6:4 v/v) Solvent BuQH - HAc - H20 (4:1:2 v/v)
Fig. 3 Thin-layer chromatograms for the crude extract
and purified components from Coptis chinensis.
Two solvent systems were employed.
Adsorbent: silica gel G (type 60)
Detection: 1. UV light
2. Dragendorff spray
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abundant component in Coptzs chinensis (e.g. Zhao, 1951). In
the present monitoring procedure, berberine hydrochloride did
show-'the same chromatographic mobility as B1 in all solvent
systems tested, and the relative quantities of B1: B2: B3
was indeed approximately 9: 2.5: 1.
3.1.3 Spectroscopic analysis
3.1.3.1 UV-visible spectra (Fig. 4)
The spectrum for B1 was identical to the Sigma prepara-
tion of berberine hydrochloride with only slight difference in
molar extinction coefficient.
Mdnu
For berberine, A nm(log e) :229 (4.53), 264 (4.51)max
343 (4.49), 415 (3.80). The UV absorption characteristics
were compatible with that reported in literature (Holubek and
Strouf, 1965).
Ine content of crystalline water in B1 was not yet
defined and the estimation of molar extinction coefficient
a McOH
was based on an anhydrous molecular weight. inm(log c):
max
229 (4.49), 264 (4.47), 343 (4.45), 415 (3.78). The peak
ratios were compatible with berberine.
3.1.3.2 IR spectra (Fig. 5)
Both B1 and berberine showed similar IR absorption
characteristics that were compatible-with that reported in
KRr n -1













Fig. 4 UV-visible spectra of berberine( )
and B1 compound(----) from Coptis
chinensis. Substances were dissolved
in methanol to make 0.01 mg/ml solu-
tions.
34
4000 3500 3000 2500 2000 1600 1600 1400 1200 1000 800 600 500 400 300
WAVEN FABER CM
Fig. 5 Infrared spectrum- of B1 compound it was
similar to that of berberine hydrochloride
(Sigma). Sample discs were prepared by
mixing and pressing the substances with
KBr.
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Fig. 6 NMR spectrum of B 1 compound it was
identical with that of berberine
hydrochloride (Sigma). Substances
were dissolved in deuter.omethanol.
(Courtesy of Prof. U. Sankawa, Uni-
versity of Tokyo)
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1504 (CO aryl)) 1274, 1068 (COalkyl), 1108 (acet a l). The
absorption band near 3400 cm-1 might be due to the existence
of water in the sa.mn1 P-
3.1.3.3 NMR spectra (Fig. 6)
Bl and berberine showed identical NMR spectra. S CD 30DTMS
4.08 (3H,s), 4.19 (3H,s), 6.06 (2H,s), 6.88 (1H,s), 7.55 (1H,
s), 7.94 (2H,q), 8.56 (1H,s), 9.61 (1H,s). The peaks at
53.30 might be due to CH3OH in the solvent. The peak at 54.9
might indicate hydrogens at C5 and C6, and/or HOD in the
sample solution.
All chromatographic and spectroscopic evidence sug-
gested B1 should be berberine. B2 was identified as, coptisine
through the courtesy of Professor U. Sankawa, University of
Tokyo.
3.2 PHARMACOLOGICAL OBSERVATIONS
3.2.1 Effects of intravenous infusion of Coptis chinensis
crude extract on blood pressure and heart rate
.Intravenous infusion of either physiological saline,
or•that-blank solution having the same ionic composition as
the drug solution, caused no significant changes on blood
pressure or heart rate. On the other hand, intravenous infu-
sion of the crude extract caused a dose-dependent decrease in




















0 12 604824 36
Ti ine of infusion( min
Fig. 7 Typical examples of Coptis chinensis crude
extract, B1, B2 and berberine (Sigma) on
arterial pressure. The crude extract was
infused into numbutalized rats through a
right femoral vein catheter at an infusion
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Fig. 8 Effect of Coptis chinensis crude
extract on arterial blood pressure.
Material was infused into n,embu-
talized rats (n= 8) through a
right femoral vein catheter at a
rate of 9.0 mg/kg/hr. Results are
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Accumulated dose of C. chinensis extract( mg/kg b w )
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Time of infusion (min)
Fig. 9 Effect of Coptis e hi nens i s crude extract
on heart rate. Material was infused into
nembutalized rats (n= 8) through a right
femoral vein catheter at an infusion dose
of 9.0 mg/kg/hr. Results are expressed as
mean± S.E.M. at each time point.
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significant after 2.3 mg/kg had been infused within 15 min.
The decrease in systolic pressure at this dose level is
statistically significant (p < 0.01). The hypotensive effect
was already significant at a. lower dose level (1.1 mg/kg) and
manifested as a decrease in diastolic pressure (p < 0.01).
The change in blood pressure was more pronounced in the dose
range 2.3- 4.5 mg/kg, thereafter the change became more
gradual and a total decrease of 44± 3% (n = 8) in mean
arterial pressure was observed at an accumulated dose of
9.0 mg/kg at the end of infusion. However, the pulse pressure
did not change significantly within this dose.range (p > 0.1).
At doses below 2.3 mg/kg, the heart rate seemed to
increase slightly as the infusion progressed, but the change
was not statistically significant (p 0.1 at 2.3 mg/kg)
(Fig. 9). Thereafter significant decrease in heart rate was
observed and a decrease of 28± 8% (n = 8) was observed after
receiving a dose of 9.0 mg/kg within one hour. The brady-
cardiac effect occurred after the onset of hypotensive effect
(at an accumulated dose of 2.3 mg/kg, p 0.1 for heart rate
whereas p 0.01 for systolic pressure).
3.2.2 Effects of intravenous infusion of
ber.beri ne on blood nressrP anrI hAnr+ rn+A
Intravenous infusion of berberine caused a dose-
dependent decrease in blood pressure.(Figs. 7 & 10). The
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Fig. 10 Effect of berberine on arterial
blood pressure. Berberine was
infused into nembutalized rats
(n = 11) through a right femoral
vein catheter at an infusion dose
of 10.0 mg/kg/hr. Results are











2.0 4.0 6.0 8.0
0
Accumulated dose of berberine hemisulfate(mg/Kg b.w.)
10.0
Time of intusion (min)
20 40 60
Fig. 11 Effect of berberine on heart rate. Berberine
was infused into nembutalized rats (n = 11)
through a right femoral vein catheter at an
infusion dose of 10.0 mg/kg/hr. Results are
expressed as mean ± S.E.M. at each time point.
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at 24 minutes (p 0.01 for systolic pressure) The change
became more gradual thereafter, A decrease of 28± 3%
(n= 11) in mean arterial pressure was observed after
10.0 mg/kg had been infused in 1 hour. As in the case of
crude extract, the decrease in diastolic pressure was more
pronounced at a lower dose level than that in systolic pres-
sure. At 4.0 mg/kg berberine, decrease in diastolic pressure
was already very significant (p< 0.001) whereas the hypoten-
sive effect was only beginning to manifest a, decrease in
systolic pressure (p 0.01). However, berberine caused a
slight increase in pulse pressure although this was not
statistically significant (p > 0.1).
Bradycardia became significant at an accumulated dose of
4.0- 6.0 mg/kg (p< 0.01 at 6.0 mg/kg)(Fig. 11). Further
change in heart rate became insignificant beyond the dose
8.0 mg/kg. A decrease of 18± 8% (n= 11) in heart rate was
observed at an accumulated dose of 10.0 mg/kg at 1 hour.
Again, decrease in heart rate (p >0.1 at 4.0 mg/kg) occurred
after the decrease in blood pressure (p <0.01 at 4.0 mg/kg)
was observed.
3.2.3 Effect of intravenous infusion of
berberine on blood pressure in the presence
of ansolysen
Intravenous infusion of ansolysen per se caused a














0 2.0 4.0 6.0 8.0 10.0
Accumulated dose of berberine mg/Kg b.w.
0
100
Accumulated dose of ansolysen (ug/Kg b.w.)
0 20 40 60
Time of infusion (min)
0 200 300 400 500
47
48
Fig. 12 Effects of berberine on arterial blood
pressure. Controls and tests were performed
on same rats (n = 7) with a difference of
about 6 hours in between. Ansolysen was
infused through a femoral vein catheter
at a dose of 500 ug/kg/hr, berberine
20 mg/kg/hr. Berberine was infused through
another femoral vein catheter after maximal
blood pressure response to ansolysen had
been reach (250 ug/kg) at 30 minutes.
Resultes are expressed as mean ± S.E.M. at
each time point.
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accumulated dose of 250 ug/kg was reached at 30 minutes., At
this dose level a decrease of 19± 6% (n= 7) in mean arterial
pressure was observed (Fig. 12). Higher doses did not
decrease the blood pressure further. In fact, the blood
pressure showed a tendency to increase slightly at higher
doses although this increase was not statistically signifi-
cant (p > 0.05 for both systolic and diastolic pressures).
Concomitant intravenous infusion of berberine, which
started after ansolysen had caused maximal decrease in blood
pressure (250 pg/kg), could further decrease the blood pres-.
sure in a dose-dependent manner. This additional decrease in
blood pressure was small, but statistically significant (at
2.0 mg/kg of berberine, p -0.05 fo.r both systolic and dias-
tolic pressures). An overall decrease of 34± 6% (n= 7) in
mean arterial pressure was observed after 500 pg/kg of anso-
lysen and 10.0 mg/kg of berberine had been infused in 1 hour.
Such a magnitude of hypotensive effect could not be produced
by a maximal dose of berberine or ansolysen acting individ-
ually.
3.3 EFFECTS OF BERBERINE AND COPTISINE ON
CHOLINESTERASE ACTIVITY
3.3.1 Bovine erythrocyte acetylcholinesterase
As shown in Fig. 13, B1, berberine (Sigma) and coptisine
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Fig. 13 Dose-dependent inhibitory effects of
B1,berberine (Sigma) and coptisine
(B2) on bovine erythrocyte acetyl-
cholinesterase. Assays were made at
37°C and pH 7.6 on the hydrolysis of
5 x 10-4 M acetylthiocholine. Each












Fig. 14 Lineweaver-Burk plots for inhibition of bovine
erythrocyte acetylcholinesterase by B1 and
berberine (Sigma) (0.33 ug/ml). Assays were
made at 37°C and pH 7.6 on the hydrolysis of
acetylthiocholine. Each data point represents












Plots of reciprocals of rate vs.Fig. 15
concentration of berberine at
different substrate concentrations
for bovine erythrocyte acetylcholin-
esterase. Assay were made at 37°C
and pH 7.6 on the hydrolysis of
1 x 10-4M0.5 x 10-4M
and2.5 x 10-4M
5x10-4M of acetylthio-
choline. Each data point represents
the average of two assays.
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manner. The degree of inhibition was similar for B1 and
commercial berberine which showed a 50% inhibition at a
concentration of 0.6 p g/ml. The degree of inhibition by
Copt is ine was only 1/9 that of berb erine it showed a. 50%
inhibition at 5 pg/ml.
The Michelis-Menton constant of bovine erythrocyte
acetylcholinesterase for the hydrolysis of acetylthiocholine,
as determined by the Lineweaver-Burk plot, was 1.4 x 10 4 M
(Fig. 14). The inhibition by berberine was. found to be non-
competitive having a Ki. of 9.4 x 10 7 M. A consistent K.
value was observed over a substrate concentration range of
0.5 x 10 4 M to 5.0 x 10 4 M (Fig. 15).
3.3.2 Rat auricular cholinesterase
At a concentration of 0.33 pg/ml, berberine showed a
13% inhibition on total auricular cholinesterase activity
(p <0.01). The specific anti-cholinesterase alone caused a
21% inhibition at a concentration of 10 5 M. Upon the addi-
. tion of berberine, a further 57o inhibition was observed, this
further inhibition was small but significant (p 0.01).
The non-specific cholinesterase inhibitor iso-OMPA alone
caused a 76% inhibition on total auricular cholinesterase
activity at a concentration of 6.7 x 10 6 M. Berberine
caused a further 6% inhibition which was statistically signi-














Fig. 16 Effect of berberine on rat auricular cholin-
esterase activities. Enzyme activities were
assayed in the absence of inhibitor (control), in
the presence of maximum concentration of selective
inhibitor on true (by 1, 5-bis- (4-allyldimethyl-
ammoniumphenyl)-pentane-3-one dibromide, anti-AChE)
or on non-specific cholinesterase (by iso-OMPA).
Assays were made at 37°C and pH 7.6 on the hydro-
lysis of 5 x 10-4 M acetylthiocholine. Enzyme
preparations were obtained by pooling the auricles
of 11 rats. Results are expressed as mean ± S. E. M.
(n= 4). In each experiment the control is taken
as 100% activity.
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Under maximal inhibition of non-specific cholinesterase
activity by iso-OMPA, both B1 and berberine (Sigma) showed a
similar degree of inhibition on auricular cholinesterase
activity a 50% inhibition was observed at about 1 ug/ml.
The inhibition by coptisine was 9 times weaker, same as the
case in bovine erythrocyte acetylcholinesterase, it showed a
50% inhibition at 9 ug/ml (Fig. 17).
The Michelis-Menton constant of auricular acetylcholin-
esterase for the hydrolysis of acetylthiocholine as determined
by the Lineweaver-Burk plot was 8.0 x 10 -5 M (Fig. 18). It was
slightly less than that for bovine erythrocyte acetylcholin-
esterase. The inhibition by berberine was also found to be
non-competitive, having a K. of 1.8 x 10 -6 M. It was about
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Fig. 17 Dose-dependent inhibitory effects of
B1, berberine (Sigma) and coptisine
(B2) on rat auricular acetylcholin-
esterase. Assays were made at 37°C
and pH 7.6 on the hydrolysis of
5 x 10-4 M acetylthiocboline in the
presence of 6.7 x 10-6 M iso-OMPA.
The enzyme preparations were obtained
by pooling the auricles of 11 rats.












Fig. 18 Lineweaver-Burk plots for inhibition
of rat auricular acetylcholinesterase
by berberine (Sigma) (0.33 ug/ml).
Assays were made at 37°C and pH 7.6
On the hydrolysis of acetylthiocholine
in the presence of 6.7 x 10-6 iso-
OMPA. Enzyme preparations were
obtained by pooling the auricles of
11 rats. Each data point represents
the average of two assays.
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4. DISCUSSIONS
4.1 ACTIONS OF Coptis chinensis CRUDE EXTRACT
AND BERBERINE ON BLOOD PRESSURE
It has been demonstrated that intravenous injection of
berberine exerted a transient hypotensive action in dog
(Jang, 1953). In the present animal model, transient hypo-
tensive effect was also observed when the crude extract or
berberine was administered as a single intravenous injection.
However, when a higher dose of crude extract (above 4.5 mg/kg)
or berberine (above 6.0 mg/kg) was given in such a way, pro-
longed hypotensive effect persisted up to several hours
although a transient drop in blood pressure was still present.
For this reason, continuous intravenous infusion was preferred
in order to observe any gradual change in blood pressure.
As shown in Fig. 8, up to 44% decrease in mean arterial
pressure was observed when 9.0 mg/kg of crude extract had been
given within 1 hour. The hypotensive effect was first mani-
fested in diastolic pressure at a lower dose level as compared
to comparable decrease in systolic pressure. When change in
pulse pressure was not yet significant, the decrease in dias-
tolic pressure appeared already suggesting a decrease in peri-
pheral resistance before any change in cardiac performance
occurred. This idea was consistent with the time course for
the change in heart rate. At an early stage of infusion when
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the crude extract had not yet accumulated to an effective
hypotensive dose level (e.g. 2.3 mg/kg at 8 minutes), the
heart rate increased slightly, which might indicate a reflex
action due to a probable decrease in peripheral resistance
,(De Quattro et aZ., 1977). However, at 15 minutes after the
onset of infusion, the blood pressure had decreased-to a
significant degree while at this time the heart rate still
remained elevated. This observation suggested that, at least
at the initial phase of drug action and/or at low dose level,
the decrease in peripheral resistance constituted an important
component, if not the principal component, of the overall
hypotensive effect. But the relative contribution between
cardiac and peripheral components to the slow-acting hypoten-
sive effect could not be differentiated in this study.
Since berberine is the principle constituent in Coptis
chinensis, it is reasonable as a first attempt to identify the
pharmacological effects of Copti's chinensis with berberine.
The hypotensive activity of berberine had been documented
(Jang, 1953). In the present study compound B1 from Coptis
chinensis was shown to be identical with berberine by differ-
ent methods of chromatographic and spectroscopic analyses.
Prelminary test with B1 had also found similar hypotensive
activity comparable to berberine (Fig. 7). Consequently,
berberine was used instead of B1 in all experiments.
The pharmacological action was similar for berberine and
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crude extract. In both cases the initial increase in heart
rate at the first 10 minutes of infusion did not cause an
elevation in blood pressure. On the contrary a significant
decrease in blood pressure occurred before any significant
•decrease in heart rate was observed. But in the case of
berberine, a gradual increase in pulse pressure was observed
although the change was not statistically significant. Pulse
pressure remained constant, or slightly decreased when the
crude extract was administered.
As compared on a unit weight basis, the hypotensive
activity of Coptis chinensis crude extract was found to be
more pronounced than that of berberine. A 44% decrease in
mean arterial pressure was observed at a crude extract dose
level of 9.0 mg/kg, whereas only 28% decrease in mean arterial
pressure was observed at a berberine dose level of 10.0 mg/kg.
Phytochemical analysis showed that berberine constituted 53%
by weight in the crude extract. Therefore a dose level of
crude extract at 9.0 mg/kg toward the end of infusion was
equivalent to a berberine dose level of 4.5 mg/kg. The other
components, which constituted one half by weight, would contri-
bute to additional hypotensive effect on top of berberine.
Compound B2, which was identified as coptisine, was
tested in the same dose range as berberine. It did not show
observable hypotensive effect, as indicated in Fig. 7. However,
slight tachycardiac effect was observed at the latter stage of
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infusion. Therefore it should-not be excluded the possibility
that coptisine did exert hypotensive effect by decreasing peri-
pheral resistance but this effect was overridden by the reflex
tachycardia. If there is another hypotensive principle other
than berberine in the crude extract, it is probably contributed
by coptisine and B3 fraction. However, it cannot be exclude
that coptisine or B3 will act synergistically with berberine to
potentiate its hypotensive activity. Such a hypothesis has not
been tested.
4.2 ACTION MECHANISM OF BER.BERINE
It might be possible to dif'ferentia,te the peripheral
action of berberine if under maximal ansolysen blockage no
further decrease in blood pressure was observed. In the present
case, berberine can still manifest a hypotensive effect under
maximal ganglionic blockage. There are several explanations:
(1) When ansolysen blockage reaches maximum in a physio-
logical sense, the hypotensive effect of berberine is a good
indication of its peripheral action. Although it is unlikely
that absolute ganglionic blockage would occur, a possible
peripheral action of berberine was suggested by the early phase
of its hypotensive action where hypotension appeared before
bradycardia. This hypothesis can be verified by studying the
effect of berberine on local circulation.
(2) The present observation does not exclude the
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possible CNS effect of berberine. Even though under maximal
ganglionic blockage, berberine may still exert its hypotensive
effect at the medullary level. This can be achieved by the
enhancement of cardiac vagal control pathway which bypasses
the influence of ganglionic blockage. This hypothesis is sug-
gested by berberine-induced bradycardia at the later phase of
its action. This hypothesis can be confirmed by spinal section
together with sympathetic trunk dorsal root section.
(3) The bradycardiac effect also raises the possibility
that berberine acts on the synaptic junction in the heart.
Since ganglionic blockage is maintained by ansolysen, ber-
berine would act on the cardiac muscarinic site to enhance the
vagal function, thus potentiating the ganglionic blockage
effect. This possibility was suggested by early studies on
isolated mammalian heart preparations (Jang, 1941). It is
reasonable to attribute the acetylcholine-enhancing effect of
berberine to its inhibitory action on acetylcholinesterase.
The hydrolysis process of acetylcholine is known to involve
the anionic and esteratic sites of acetylcholinesterase (e.g.
Adams and Whittaker, 1950 Wilson and Bergmann, 1950 a,b). A
number of quaternary amines and isoqui'nolines were found to
inhibit cholinesterase activity reversibly by interacting with
the anionic site (Main, 1976).
Therefore, as a biochemical approach, the hypotensive
effect of berberine may be partly explained by the inhibitory
action of berberine on acetylcholinesterase.
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4.3 ACTION OF BERBERINE ON ACETYLCHOLINESTERASE
In this study, the inhibitory action of berberine on
bovine erythrocyte acetylcholinesterase was confirmed. The
K value was found to be 1.4 x 10 4M it was consistent with
M
previously reported value (ELloran et al., 1961). Substrate
inhibition on acetylcholinesterase was documented but under
the present conditions of experiment (5 x 10 4M of acetylthio-
choline), the substrate concentration was not enough to pro-
duce such an inhibition (Wright and Sabine, 1948). Therefore
the application of Michelis-Menton kinetics was valid. The
inhibitory effect of coptisine on bovine erythrocyte acetyl-
cholinesterase was several times weaker than that of berberine.
Since coptisine did not manifest hypotensive effect at the
same dose range as berberine, it provides a good evidence
correlating the hypotensive action of berberine with its anti-
cholinesterase activity.
Ord and Thompson (1950) has examined the cholinesterase
activity in various rat tissues. They found an exceedingly
high cholinesterase activity towards acetylcholine in heart,
especially the auricle, as compared to many other tissues.
The relative amount of cholinesterase activity and its distri-
bution seemed to coincide with the amount of vagal innervation
in different parts of the heart. This has been demonstrated in
rabbit (Antopol et aZ.., 1939), human and dog (Sinha et al.,
1976). I f berberine can inhibit cholinesterase activity in
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the heart, the hypotensive activity of berberine may be partly
attributed to the enhancement of vagal control of the heart.
In a first series of experiments it was found that a 13% inhi-
bition on total auricular cholinesterase was observed at a
berberine concertration of 0.33 pg/ml. Since this concentra-
tion was presumably much lower than that in blood when brady-
cardia occurred (4- 6 mg/kg), the circulating concentration
of berberine at this dose level must be effective in inhibi-
ting auricular acetylcholinesterase. Non-specific cholin-
esterase activity is also exceedingly high in rat auricle
(Ord and Thompson, 1950), and the function of this non-
specific enzyme is still unsettled (Main, 1976). Therefore ii
would be necessary to determine what kind of cholinesterase
was inhibited by berberine. For this purpose, the use of
specific enzyme inhibitors became mandatory. In the presence
of 10/-5/M of a specific inhibitor of acetylcholinesterase
(1,5-bis-(4-allyldimethylammoniumphenyl)-pentane-3-one
dibromide) which could maximally inhibit true acetylcholin-
esterase activity, the net difference in acetylcholine hydro-
lysed in the presence and absence of this inhibitor might
represent the contribution by berberine inhibition on acetyl-
cholinesterase (McLaughlin and Bosmann, 1976). Under this
condition, 0.33 rg/ml of berberine showed a 6% reduction in
auricular non-specific cholinesterase activity, this meant
that the inhibition of berberi.ne on non-specific cholines-
terase was quite unimportant, although this'inhibition was
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statistically significant. This observation was further
validated by measuring berberine inhibition in the presence of
6.7 x 10-3 M of iso-OMPA, a non-specific cholinesterase inhi-
bitor (Sinha et a l., 1976). Under this condition, a 27% inhi-
bition of specific acetylcholinesterase was produced by the
same concentration of berberine. It is quite evident that
berberine is a more potent inhibitor of specific acetyl-
cholinesterase. There is no generalization on the structure-
specificity relationship for cholinesterase inhibitor although
most quarternary amine inhibitors and bis-benzylisoquinoline
inhibitors are found more potent towards.acetylcholinesterase
than non-•specific cholinesterase (Main, 1976). Furthermore,
coptisine, having the same ring structure as berberine, is a
much weaker inhibitor of acetylcholinesterase. This' suggests
that the enzyme-inhibitory, and probably also the hypotensive,
effect may not lie solely on the protoberberine skeleton.
The inhibitory potencies of berberine and coptisine on
auricular acetylcholinesterase were. both found less than that
on bovine erythrocyte acetylcholinesterase. This might be due
to the difference in nature of the enzyme, or the different
degree. of membrane binding.' However, in both enzyme prepara-
tions, the concentration ratio of berberine to coptisine at
50% inhibition remained unchanged.
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4.4 GENERAL DISCUSSION
Due to the complicate nature of regulation in cardio-
vascular function, subsequent changes in the action of a drug.
do not necessarily indicate separate mechanism of action. In
.an attempt to interpret the locus of berberine action, several
lines of reasoning are presented hereunder.
Firstly, the transient hypotensive effect distinguishes
berberine action from a reserpine-like action. The depletion
of sympathetic catecholamines is a slow process. In the
present animal model reserpine was not effective until about
10 minutes when a detectable hypotensive effect could be
observed. This lag period was independent of the intravenous
injection. No significant lag period was observed with
berberine.
Secondly, although the rapid onset of drug action may be
partly contributed by direct vasodilatation, it is doubtful
that vasodilatation would be the principal hypotensive. action.
Under normal physiological conditions, the direct and immediate
.sequelae of vasodilatation should be tachycardia due to baro-
receptor reflex (De Quattro et aZ., 1977 Wollam et aZ.,
1977). In this study, the tachycardiac effect of berberine
was not significant but bradycardia accompanied hypotension.
Thirdly, decrease in blood pressure under conditions of
maximal ansolysen blockage suggested that the preganglionic
component was not involved in the hypotensive action of
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berberine. If berberine acts to reduce the preganglionic
release of acetylcholine, or acts on the ganglion in some way
to retard the effect of acetylcholine, berberine must be able
to act as a ganglionic blocker. In this case, berberine
.should produce immediate bradycardiac effect which was not
observed in these experiments.
Fourthly, although the hypotensive effect of berberine
may presumably be correlated with the anticholinesterase
activity exerted on the heart (a muscarinic site), it does not
exclude the possible action on other sites like that in the
CNS or in the vascular bed (Brimblecombe, 1974). For example,
in this animal model both eserine and neostigmine (typical
anticholinesterase agents) failed to induce any significant
changes in blood pressure and heart.rate up to a dose of
160 pg/kg (the generally used dosage of neostigmine methylsul-
fate for human is about 17 pg/kg by intramuscular injection).
Therefore it would be interesting to know what sites other that
the heart will berberine exert its anticholinesterase activity
in a system where eserine and neostimi ne were i nef fec t i v_
One rationale in the treatment of hypertension is the
principle of combination therapy by which antihypertensive
effect can be maximized and adverse effects can be minimized
(e.g. Dollerg, 1977 Frohlich, 1977). In this case, it is
noted that the hypotensive activity of crude extract of
Coptis chinensis is more potent than that of berberine per se
70
as compared on a unit weight basis. It is quite possible that
a millennial subconscientious selection leads to multiple-
component, multiple-site of action in the use of traditional
Chinese medicine. In this case, it may be arbitrary to
identify the hypotensive effect of Coptis chinensis entirely
with one single constituent.
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5. SUMMARY
The acute hypotensive effects of Coptis chinensis crude
extract and berberine were studied in nembutalized rats. It
was observed that intravenous infusion of crude extract
decreased arterial pressure in a dose-dependent manner. The
initial stage of drug action might involve vasodilatation as
suggested by indirect evidence. The second stage might involve
the modulation on cardiac performance as suggested by the
bradycardiac effect. Phytochemical studies showed that ber-
berine was the most abundant alkaloid in the crude extract.
Berberine decreased blood pressure in a manner similar to that
for crude extract. The possible modulation on cardiac per-
formance was suggested in this case by the inhibition of
berberine on auricular acetylcholinesterase. Coptisine was
a weak inhibitor of acetylcholinesterase. The more pronounced
effect by crude extract on a weight basis suggested the
existence of other hypotensive principles in Coptis chinensis.
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